Nephrology Drugs Market Expected to Reach $14,501.75 Million by 2030

According to a new report published by Allied Market Research, titled, “Global Nephrology Drugs Market by drug class, route of administration, distribution channel, and region: Global Opportunity Analysis and Industry Forecast, 2021–2030,” the global nephrology drugs market was valued at $14,501.75 million in 2020, and is projected to reach $23,405.42 million by 2030, registering a CAGR of 5.0% from 2021 to 2030.

Considerable rise in cases of diabetes, hypertension, and chronic kidney diseases; rise in cases of kidney failures; changes in lifestyle of people to sedentary lifestyles; and surge in geriatric population are expected to propel the growth of the nephrology drugs market. The market for nephrology drugs has witnessed tremendous growth in the recent years, due to surge in demand for the medication.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global nephrology drugs market. The COVID-19 pandemic has stressed healthcare system in the world and increased the need to identify the strain of new coronavirus. As per the report published in 2021, 4–37% of COVID-19 cases involve the kidneys, and Acute Kidney diseases have an incidence of 50% in hospitalized COVID-19 patients. Thus, it is found that the COVID-19 virus is having an impact on the kidney of the patients, which, in turn, is expected to increase the burden of kidney disorder in near future, fueling the market growth.

Pharmaceutical and biotech companies along with governments around the globe are working to address the COVID-19 outbreak, from supporting the drugs development to medicine supply chain planning. The pharmaceutical and biotechnology industries are expected to witness a significant growth in the future due to the demand for drugs for kidney disorder treatment. This, in turn, is expected to have a significant impact on the nephrology drugs market.

The major factors driving the growth of the nephrology market include rise in R&D activities for the launch of novel drugs and improvement in existing drugs. Moreover, rise in number in approval from government regulatory institutes is creating lucrative opportunities for the nephrology drugs market. For instance, in April 2021, AstraZeneca, a global leading life science company, received approval from the U.S. FDA for Farxiga. Moreover, in in July 2021, Bayer, received and approval from U.S. FDA for a new drug application drug, Finerenone. In addition, increase in investment in R&D activities increases the demand of nephrology drugs, thereby providing lucrative opportunities for the market growth. However, side effects due to the treatments and expensive cost of the drugs are causing restrain in the market growth.

Chronic kidney diseases are being considered as one of the leading public health issues worldwide. According to the National Library of Medicine, the global estimated prevalence of chronic kidney disease is 13.4% (11.7-15.1%). Along with this, patients suffering from end-stage kidney disease who need renal replacement therapy is estimated between 4.902 and 7.083 million. Chronic kidney disease directly affects cardiovascular health, thus impacting the global burden of morbidity and mortality worldwide. Moreover, rise in chronic kidney diseases is majorly attributed to surge in prevalence of diabetes mellitus, obesity, hypertension, infections, and aging. This has created a surge in demand of nephrology drugs, which is anticipated to propel the market growth in the near future

Increase in the number of approvals and products launches among key players and biopharmaceutical companies and technological advancements in nephrology drugs fuel the growth of the market.

Surge in demand and need for nephrology drugs has been witnessed throughout the world along with their growing awareness in developing economies owing to ease and applicability of nephrology drugs. The advancements have been benefiting research endeavors in Asia and other developing regions of the world. In July, 2019, Baxter announced its full support of the Administration’s Advancing American Kidney Health Initiative. In fiscal year 2020, Medicare invested more than $114 billion on patients with chronic kidney disease annually, which included $35 billion on end-stage renal disease (ESRD) patients. This is expected to further provide numerous growth opportunities during the forecast period

The nephrology drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region. On the basis of drug class, the market is divided into ACE inhibitors, calcium channel blocker, beta blockers, diuretics, and others. The ace inhibitors segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to rise in the prevalence of various cardiovascular and hypertension conditions and changing lifestyles.

By route of administration, the market is classified into oral, parenteral, and others. The oral segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to key players focusing on novel drugs launches.

Depending on distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacy segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to developments in the medical infrastructure and rise in public healthcare expenditure.

North America accounted for a majority of the global nephrology drugs market share in 2020 and is anticipated to remain dominant during the forecast period. This is attributed to awareness regarding the chronic kidney diseases in the region.

Key Findings Of The Study

• By drug class, the ace inhibitors segment was the highest contributor to the market in 2020.
• On the basis of route of administration, the oral segment dominated the market in 2020.
• Depending on distribution channel, the retail pharmacy segment was the highest contributor to the market in 2020.
• Region wise, North America garnered largest revenue share in 2020.